Zusammenfassung
Moderne Therapiekonzepte in der Behandlung der Peritonealkarzinose unterschiedlicher Malignome sehen neben dem systemischen Einsatz neuerer Chemotherapeutika auch in selektierten Fällen die Durchführung zytoreduktiver operativer Maßnahmen in Kombination mit einer hyperthermen intraperitonealen Chemoperfusion (HIPEC) vor. Aufgrund der teilweise relativ hohen peri- und postoperativer Morbidität und Letalität, wird nach aktuellem Kenntnisstand eine Lernkurve von mindestens 100 bis 150 Prozeduren gefordert.
Durch die Optimierung der bestehenden logistischen Voraussetzungen, einer sorgfältigen Vorbereitung und einer systematischen Schulung des ärztlichen und pflegerischen Personals gelingt es, perioperative Risiken und somit die Komplikationsraten nachhaltig zu senken. Diese komplexe Prozedur sollte vorzugsweise in spezialisierten Zentren durchgeführt werden.
Abstract
Cytoreductive surgery (CRS) combined with perioperative intraperitoneal chemotherapy (PIC) is a treatment option for peritoneal surface malignancy. Despite the survival benefits, this treatment was previously associated with a high morbidity and mortality rates, and the perception of the poor perioperative outcomes associated with this regimen remains. Careful patient selection with an optimal level of postoperative care must be advocated to avoid undesirable complications of this treatment.
However, for this treatment to be accepted as standard of care, teams undertaking this treatment strategy must aim to minimize morbidity and mortality by learning from the experience of established centers and using the “global learning curve”. The HIPEC Registry and accreditation of centers will improve the quality of the treatment.
Literatur
AWMF Leitlinie „Kolorektales Karzinom“. http://www.awmf.org/leitlinien/detail/ll/021-007OL.html
Canda AE, Sokmen S, Terzi C et al (2013) Complications and toxicities after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 20(4):1082–1087
Chan DL, Morris DL, Rao A et al (2012) Intraperitoneal chemotherapy in ovarian cancer: a review of tolerance and efficacy. Cancer Manag Res 4:413–422
Chua TC, Yan TD, Saxena A et al (2009) Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality. Ann Surg 249(6):900–907
Elias D, Blot F, El Otmany A et al (2001) Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer 92:71–76
Esquivel J, Vidal-Jove J, Steves MA et al (1993) Morbidity and mortality of cytoreductive surgery and intraperitoneal chemotherapy. Surgery 113:631–636
Glehen O, Cotte E, Schreiber V et al (2004) Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin. Br J Surg 91:747–754
Glehen O, Gilly FN et al (2010) Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol 17(9):2370–2377
Glehen O, Osinsky D, Cotte E et al (2003) Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol 10:863–869
Glockzin G, Schlitt HJ, Piso P (2009) Peritoneal carcinomatosis: patients selection, perioperative complications and quality of life related to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol 7:5
González Bayón L, Sugarbaker PH, Gonzalez Moreno S et al (2003) Initiation of a program in peritoneal surface malignancy. Surg Oncol Clin N Am 12(3):741–753 (Review)
Harmon RL, Sugarbaker PH (2005) Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. Int Semin Surg Oncol 2(1):3
Hayes-Jordan A, Green H, Ludwig J et al (2012) Toxicity of hyperthermic intraperitoneal chemotherapy (HIPEC) in pediatric patients with sarcomatosis/carcinomatosis: early experience and phase 1 results. Pediatr Blood Cancer 59(2):395–397
Jacquet P, Stephens AD, Averbach AM et al (1996) Analysis of morbidity and mortality in 60 patients with peritoneal carcinomatosis treated by cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy. Cancer 77:2622–2629
Konate A, Poupon J, Villa A et al (2011) Evaluation of environmental contamination by platinum and exposure risks for healthcare workers during a heated intraperitoneal perioperative chemotherapy (HIPEC) procedure. J Surg Oncol 103(1):6–9
Kusamura S, Baratti D, Hutanu I et al (2012) The importance of the learning curve and surveillance of surgical performance in peritoneal surface malignancy programs. Surg Oncol Clin N Am 21(4):559–576. doi:10.1016/j.soc.2012.07.011
Mohamed F, Moran BJ (2009) Morbidity and mortality with cytoreductive surgery and intraperitoneal chemotherapy: the importance of a learning curve. Cancer 15(3):196–199 (Review)
Moradi BN III, Esquivel J (2009) Learning curve in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Surg Oncol 100:293–296
Moran BJ, Mukherjee A, Sexton R (2006) Operability and early outcome in 100 consecutive laparotomies for peritoneal malignancy. Br J Surg 93:100–104
Pelz JO, Stojadinovic A, Nissan A et al (2009) Evaluation of a peritoneal surface disease severity score in patients with colon cancer with peritoneal carcinomatosis. J Surg Oncol 99(1):9–15
Pilati P, Mocellin S, Rossi CR et al (2003) Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis arising from colon adenocarcinoma. Ann Surg Oncol 10:508–513
Schmid K, Boettcher MI, Pelz JO et al (2006) Investigations on safety of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with Mitomycin C. Eur J Surg Oncol 32(10):1222–1225 (Epub 2006 Jun 19)
Smeenk RM, Verwaal VJ, Zoetmulder FA (2007) Learning curve of combined modality treatment in peritoneal surface disease. Br J Surg 94:1408–1414
Stephens AD, Alderman R, Chang D et al (1999) Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol 6:790–796
Sugarbaker PH (2005) A curative approach to peritoneal carcinomatosis from colorectal cancer. Semin Oncol 32:S68–S73
Sugarbaker PH (1998) Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol 14:254–261
Sugarbaker PH, Jablonski KA (1995) Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg 221(2):124–132
Verwaal VJ, Tinteren H van, Ruth SV et al (2004) Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. J Surg Oncol 85:61–67
Votanopoulos K, Ihemelandu C, Shen P et al (2013) A comparison of hematologic toxicity profiles after heated intraperitoneal chemotherapy with oxaliplatin and mitomycin C. J Surg Res 179(1):e133–e139
Yan TD, Links M, Fransi S et al (2007) Learning curve for cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal surface malignancy – a journey to becoming a Nationally Funded Peritonectomy Center. Ann Surg Oncol 14:2270–2280
Einhaltung ethischer Richtlinien
Interessenkonflikt. J.O.W. Pelz und C.-T. Germer geben an, dass kein Interessenskonflikt besteht. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pelz, J., Germer, CT. Morbidität und Letalität der hyperthermen intraperitonealen Chemoperfusion. Chirurg 84, 957–961 (2013). https://doi.org/10.1007/s00104-013-2513-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00104-013-2513-0